Study to Evaluate the Safety of SP-104
Phase 1, Double-blind, Randomized, 2-Period, 2-Treatment Crossover Study to Evaluate the Safety of SP-104 Compared to Immediate Release Naltrexone Capsules in Healthy Adult Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Auckland, New Zealand, 1010
- Auckland Clinical Studies (NZCR)
-
Christchurch, New Zealand, 8011
- Christchurch Clinical Studies Trust (NZCR)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able and willing to read, write, and understand the English language and provide English language written informed consent (IC) prior to beginning any study procedures.
- Male or female age 18 to 70 years (inclusive) at screening.
- Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or electrocardiogram (ECG), as deemed by the Investigator.
- Negative urine drug screen for drugs of abuse, including cocaine, marijuana, amphetamines, and barbiturates at the Screening Visit and at each check-in.
- If female, heterosexually active, of childbearing potential, not pregnant, not trying to become pregnant, or lactating, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 30 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 30 days after the last study dose. A second non-hormonal method of contraception is required if a hormonal form of birth control is used. Females of childbearing potential must have negative pregnancy tests at Screening and on admission.
- If male and heterosexually active, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 90 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 90 days after the last study dose.
- Able to swallow capsules.
- Agrees to comply with all study requirements throughout the entire study period.
Exclusion Criteria:
- A body mass index (BMI) <18 kg/m2 or >30 kg/m2 (without rounding).
- Are using prescription medications or over-the-counter products (including dietary supplements such as vitamins, minerals, herbs or other botanicals, amino acids, enzymes (extracts or concentrates), or probiotics (bacteria or yeasts), within 14 days prior to administration of the study medication.
- Currently using or have recently used opioids
- Use of any other investigational drug within 30 days prior to administration of the study medication.
- History of allergic or adverse response to naltrexone.
- History of drug or alcohol abuse (>80 g/day).
- History of sleep apnea or restless leg syndrome.
- Serology positive for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV) antibodies.
- Positive for known disease (e.g., corona virus disease 2019 (COVID-19 )).
- Subjects with current or past SARS-CoV-2 infection, if tested according to local requirements.
- Have had a serious illness in the 4 weeks preceding the Screening Visit that resulted in missed work or hospitalization (note: missed work in itself may not denote serious illness).
- Have cancer within the past 5 years (treated or untreated).
- Are females who are pregnant, plan to become pregnant during the study, or are breastfeeding.
- Are an employee, family member, sponsor, or student of the Investigator or of the clinical site.
- Are unable to understand or adhere to the requirements of the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SP-104 crossover to naltrexone immediate release
SP-104 administration followed by a crossover to naltrexone immediate release oral capsule administration
|
oral capsule once daily
oral capsule once daily
|
|
Experimental: Naltrexone immediate release crossover to SP-104
Naltrexone immediate release oral capsule administration with a crossover to SP-104 administration
|
oral capsule once daily
oral capsule once daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of treatment emergent adverse events
Time Frame: 1 week
|
1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SP-104-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.